scholarly journals Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex

Medicine ◽  
2021 ◽  
Vol 100 (50) ◽  
pp. e28290
Author(s):  
Chen Qi Zhang ◽  
Xue Yang Bai ◽  
Yong Wan ◽  
Hong Yan Li ◽  
Hongbin Sun
Keyword(s):  
Extended Release ◽  
Retention Rate ◽  
Delayed Release

scholarly journals Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis

2021 ◽  
Author(s):  
Chen qi Zhang ◽  
◽  
Xueyang Bai ◽  
Yong Wan ◽  
Hongyan Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Extended Release ◽  
Retention Rate ◽  
Meta Analysis ◽  
Small Sample ◽  
Safety And Efficacy ◽  
Delayed Release ◽  
Review Question ◽  
Different Populations ◽  
Patients With Epilepsy

Review question / Objective: We aim to systematically examine and compare the efficacy, safety and retention rate of ER divalproex (VPA-ER) and conventional DR divalproex (VPA-DR) on patients with epilepsy. Condition being studied: To our knowledge, comparison and conversion studies about VPA-ER and conventional VPA-DR are lacked. Small-sample studies analyzing the safety and efficacy of VPA-ER in different populations remain controversial. Therefore, this study aims to systematically review the safety, efficacy and retention rate of VPA-ER and VPA-DR by meta-analysis.

31.8 REAL-WORLD SAFETY PROFILE OF DELAYED-RELEASE AND EXTENDED-RELEASE METHYLPHENIDATE FOR ADHD IN CHILDREN, ADOLESCENTS, AND ADULTS

2020 ◽  
Vol 59 (10) ◽  
pp. S213
Author(s):  
Ann Catherine Childress ◽  
Victor Otcheretko ◽  
Lewis E. Warrington ◽  
Justin A. Barnes ◽  
Ryan A. Gregg ◽  
...  
Keyword(s):  
Real World ◽  
Safety Profile ◽  
Extended Release ◽  
Delayed Release ◽  
Adolescents And Adults

scholarly journals Formulation and evaluation of dexlansoprazole extended-release tablet

2021 ◽  
Vol 17 (3) ◽  
pp. 191-197
Author(s):  
Shubham Santosh Sharma ◽  
Pooja Ganesh Bhutada
Keyword(s):  
Proton Pump Inhibitor ◽  
Extended Release ◽  
Pharmacological Action ◽  
Acidic Ph ◽  
Major Function ◽  
Delayed Release ◽  
Sustain Release ◽  
Extended Release Tablet ◽  
Acid Labile ◽  
Release Tablet

Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. Shellac can be used to develop the sustain release tablet of dexlansoprazole as retardation of the drug (dexlansoprazole) was observed in the acidic pH of the stomach, and hence a sustain coated dexlansoprazole tablet was prepared and evaluated. The coating's primary function is to allow for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits faster degradation in the acidic pH of the stomach, therefore increasing pharmacological action. DSP coating with different polymers inhibits fast degradation in the stomach's acidic pH, enhancing pharmacological action. The major function of the coating is to enable for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits fast breakdown in the stomach's acidic pH, enhancing pharmacological action.

Sign in / Sign up

Export Citation Format

Share Document